Chemistry:Fluspirilene

Short description: Typical antipsychotic medication

Fluspirilene

Clinical data
Trade names	Imap
AHFS/Drugs.com	International Drug Names
Routes of administration	IM
ATC code	N05AG01 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name 8-[4,4-Bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
CAS Number	1841-19-6 Y
PubChem CID	3396
IUPHAR/BPS	85
DrugBank	DB04842 Y
ChemSpider	3279 Y
UNII	C5QA4GLR9M
KEGG	D02629 Y
ChEMBL	ChEMBL46516 Y
Chemical and physical data
Formula	C29H31F2N3O
Molar mass	475.584 g·mol−1
3D model (JSmol)	Interactive image
SMILES Fc1ccc(cc1)C(c2ccc(F)cc2)CCCN5CCC4(C(=O)NCN4c3ccccc3)CC5
InChI InChI=1S/C29H31F2N3O/c30-24-12-8-22(9-13-24)27(23-10-14-25(31)15-11-23)7-4-18-33-19-16-29(17-20-33)28(35)32-21-34(29)26-5-2-1-3-6-26/h1-3,5-6,8-15,27H,4,7,16-21H2,(H,32,35) Y Key:QOYHHIBFXOOADH-UHFFFAOYSA-N Y
(verify)

Fluspirilene (Redeptin, Imap, R6218) is a diphenylbutylpiperidine typical antipsychotic drug, used for the treatment of schizophrenia. It is administered intramuscularly. It was discovered at Janssen Pharmaceutica in 1963. A 2007 systematic review investigated the efficacy of fluspirilene decanoate for people with schizophrenia:

Fluspirilene decanoate compared to oral antipsychotics

Summary
Participant numbers in each comparison were small so power to identify clear difference is limited. Randomized controlled trial data identified no clear differences between the long-acting injection of fluspirilene and oral medication for outcomes that include adverse effects.
Outcome Findings in words Findings in numbers Quality of evidence Global outcome Leaving the study early Follow up: 6 weeks to 5 months Fluspirilene decanoate may increase the risk of leaving the study (reasons not specified), but, the difference is not clear between people given fluspirilene decanoate and those receiving oral antipsychotics. These findings are based on data of low quality. RR 1.18 (0.08 to 16.78) Low Mental state Relapse Follow up: 6 weeks to 5 months Using the depot, long-acting fluspirilene decanoate makes little difference for the outcome of 'relapse' compared with those receiving oral antipsychotics - at least for those willing to be engaged with trials. These findings are based on data of low quality. RR 1.18 (0.08 to 16.78) Low Adverse effects Needing anticholinergic drugs Follow up: 6 weeks to 5 months The depot fluspirilene decanoate does not seem to cause any more movement disorders - for which anticholinergic drugs are used - compared with oral antipsychotics. These findings are based on data of low quality. RR 0.07 (0.00 to 1.07) Low Dizziness Fluspirilene decanoate may reduce the chance of experiencing dizziness compared with the oral antipsycotics. Data are based on low quality evidence. RR 0.59 (0.37 to 0.95) Low Missing outcomes Data on quality of life, and service use (e.g. hospitalization) were not reported in trials.

See also

• Pimozide
• Penfluridol
• Spiperone
• Mosapramine (atypical antipsychotic)